Narrow search
Showing 1 - 10 of 11,041
Cover Image
Die Rolle des Staates in der Impfstoffproduktion : technologische Restriktionen und ökonomische Ableitungen
Kirchhoff, Jasmina - 2021
Die Bundesregierung und die Europäische Kommission mussten in den letzten Wochen viel Kritik bezüglich ihrer Impfstoffbeschaffungsstrategie zur Eindämmung der Corona-Pandemie einstecken. Vor dem Hintergrund zu schleppend erscheinender Impfstofflieferungen und der zunehmenden Gefahr durch die...
Persistent link: https://www.econbiz.de/10012434819
Cover Image
Parallel imports and manufacturer rebates : evidence from Germany
Birg, Laura - 2019
pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …
Persistent link: https://www.econbiz.de/10011949028
Cover Image
Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany
Herr, Annika; Suppliet, Moritz - 2012
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …-payments ; reference pricing ; regulation ; firm behavior …
Persistent link: https://www.econbiz.de/10009522774
Cover Image
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25
Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …
Persistent link: https://www.econbiz.de/10012291135
Cover Image
Arzneimittelversorgung und -produktion gefährdet : AMNOG-Reform auf dem Prüfstand
Kirchhoff, Jasmina - 2022
Erstattungsbetragsverhandlungen innovativer Arzneimittel werden als Gefahr für die zukünftige Versorgung der Patienten und für den Forschungs- und … zweckmäßigen Vergleichstherapie gleichwertige Arzneimittel schlechter gestellt werden. Zum anderen können nur noch … Arzneimittel beeinflusst darüber hinaus die Standortentscheidungen pharmazeutischer Unternehmen. …
Persistent link: https://www.econbiz.de/10013468282
Cover Image
Drug prices and pressure group activities in the German health care market : an application of the Becker model
Busch, Anne Maria - 2015
This article analyzes the shifts of power relation and influence between pharmaceutical industry (producers), pharmacies, and social health insurers (SHI) in Germany based on drug prices. Since the health care reform of 2004, these interest groups have negotiated fees and discounts among each...
Persistent link: https://www.econbiz.de/10010529890
Cover Image
Parallel imports under a manufacturer rebate and a price freeze : evidence from Germany
Birg, Laura - In: Health economics 32 (2023) 2, pp. 302-323
Persistent link: https://www.econbiz.de/10014266802
Cover Image
Is self-regulation sufficient? : case of the German transparency code
Buske, Kristin; Jentzsch, Stefan J.; Bechter, Clemens - In: Administrative Sciences : open access journal 6 (2016) 1/3, pp. 1-12
The German pharmaceutical industry is stepping ahead with its implementation of a new transparency disclosure code for cooperation between pharmaceutical companies and health care professionals (HCPs) and health care organisations (HCOs). In Germany, this transparency code ("Transparenzkodex")...
Persistent link: https://www.econbiz.de/10012015756
Cover Image
The effects of regulative instruments on stakeholders in the German pharmaceutical market
Haustein, Robert - 2013
Persistent link: https://www.econbiz.de/10009781417
Cover Image
The diffusion of generics after patent expiry in Germany
Blankart, Katharina; Stargardt, Tom - In: The European journal of health economics : HEPAC ; … 17 (2016) 8, pp. 1027-1040
Persistent link: https://www.econbiz.de/10011660160